ArticleTranslational lung cancer research2025

Real-world outcomes and association between immune-related adverse events and therapeutic efficacy of nivolumab plus ipilimumab in elderly patients (≥75 years) with advanced non-small cell lung cancer.

Soichiro Minami et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.